Vulnerable Atherosclerotic Plaque: Is There a Molecular Signature?

22Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Atherosclerosis and its clinical manifestations, coronary and cerebral artery diseases, are the most common cause of death worldwide. The main pathophysiological mechanism for these complications is the rupture of vulnerable atherosclerotic plaques and subsequent thrombosis. Pathological studies of the vulnerable lesions showed that more frequently, plaques rich in lipids and with a high level of inflammation, responsible for mild or moderate stenosis, are more prone to rupture, leading to acute events. Identifying the vulnerable plaques helps to stratify patients at risk of developing acute vascular events. Traditional imaging methods based on plaque appearance and size are not reliable in prediction the risk of rupture. Intravascular imaging is a novel technique able to identify vulnerable lesions, but it is invasive and an operator-dependent technique. This review aims to summarize the current data from literature regarding the main biomarkers involved in the attempt to diagnose vulnerable atherosclerotic lesions. These biomarkers could be the base for risk stratification and development of the new therapeutic drugs in the treatment of patients with vulnerable atherosclerotic plaques.

Cite

CITATION STYLE

APA

Chiorescu, R. M., Mocan, M., Inceu, A. I., Buda, A. P., Blendea, D., & Vlaicu, S. I. (2022, November 1). Vulnerable Atherosclerotic Plaque: Is There a Molecular Signature? International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms232113638

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free